1-6 of 6
Kevin Ebata
Close
Sort by
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

Eliana B. Gomez, Kevin Ebata, Hetal S. Randeria, Mary S. Rosendahl, E. Peder Cedervall, Tony H. Morales, Lauren M. Hanson, Nicholas E. Brown, Xueqian Gong, Jennifer Stephens, Wenjuan Wu, Isabel Lippincott, Karin S. Ku, Richard A. Walgren, Paolo B. Abada, Joshua A. Ballard, Charles K. Allerston, Barbara J. Brandhuber
Journal: Blood
Blood (2023) 142 (1): 62–72.
https://doi.org/10.1182/blood.2022018674
Published: 2023
Includes: Supplemental data
Journal Articles

LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL

Aishath S Naeem, PhD, Winnie I Nguy, Svitlana Tyekucheva, PhD, Stacey M. Fernandes, BS, Vanessa Rai, BS, Kevin Ebata, PhD, Eliana B. Gomez, PhD, Barb J. Brandhuber, PhD, Stephen M. Rothenberg, MD PhD, Jennifer R Brown, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 478.
https://doi.org/10.1182/blood-2019-124362
Published: 2019
Journal Articles

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition

Kathryn G. Roberts, Laura J. Janke, Yaqi Zhao, Aman Seth, Jing Ma, David Finkelstein, Steve Smith, Kevin Ebata, Brian B. Tuch, Stephen P. Hunger, Charles G. Mullighan
Journal: Blood
Blood (2018) 132 (8): 861–865.
https://doi.org/10.1182/blood-2018-05-849554
Published: 2018
Includes: Supplemental data
Journal Articles

Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies

Justin Taylor, MD, Christina Marcelus, Dean Pavlick, Ryma Benayed, MD, Akihide Yoshimi, MD, Emiliano Cocco, PhD, Benjamin H Durham, MD BS, Jaclyn F Hechtman, MD, Young Rock Chung, MS, Kerry Mullaney, Justin M Watts, MD, Eli L Diamond, MD, Lee A Albacker, PhD, Tariq I Mughal, MD FRCP, Kevin Ebata, PhD, Brian B. Tuch, PhD, Nora Ku, MD, Maurizio Scaltriti, PhD, Maria E. Arcila, Siraj M Ali, MD PhD, David M. Hyman, MD, Omar Abdel-Wahab, MD, Jae H. Park, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 794.
https://doi.org/10.1182/blood.V130.Suppl_1.794.794
Published: 2017
Journal Articles

Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Olga Bridges, Laura J. Janke, PhD, Kevin Ebata, PhD, Brian B Tuch, PhD, Nisha Nanda, PhD, Charles Mullighan, MBBS, MSc, MD
Journal: Blood
Blood (2016) 128 (22): 278.
https://doi.org/10.1182/blood.V128.22.278.278
Published: 2016